Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Leases (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Operating Leases data on record, last reported at $632000.0 in Q3 2025.

  • For Q3 2025, Operating Leases rose 78.53% year-over-year to $632000.0; the TTM value through Sep 2025 reached $632000.0, up 78.53%, while the annual FY2024 figure was $937000.0, 31.8% down from the prior year.
  • Operating Leases reached $632000.0 in Q3 2025 per CRVS's latest filing, down from $728000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $2.3 million in Q1 2022 and bottomed at $354000.0 in Q3 2023.
  • Average Operating Leases over 4 years is $1.1 million, with a median of $937000.0 recorded in 2024.
  • Peak YoY movement for Operating Leases: plummeted 79.04% in 2023, then soared 78.53% in 2025.
  • A 4-year view of Operating Leases shows it stood at $1.4 million in 2022, then rose by 0.07% to $1.4 million in 2023, then plummeted by 31.8% to $937000.0 in 2024, then tumbled by 32.55% to $632000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $632000.0 in Q3 2025, $728000.0 in Q2 2025, and $834000.0 in Q1 2025.